{"id":798,"date":"2016-02-23T10:30:09","date_gmt":"2016-02-23T05:00:09","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=798"},"modified":"2025-05-05T16:55:04","modified_gmt":"2025-05-05T11:25:04","slug":"antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","title":{"rendered":"Antibody-Drug Conjugate Market Insight"},"content":{"rendered":"

DelveInsight, the leading market research and consulting company has added a new report \u201cAntibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016\u201d to its portfolio.<\/strong><\/p>\n

The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes:<\/p>\n

Information on 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.<\/p>\n

Brentuximab Vedotin,developed by Seattle Genetics, is the leading product.<\/p>\n

R&D activities and technologies used along with the pipeline molecules in development.<\/p>\n

Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.<\/p>\n

Information related to collaborations, in-licensing and out-licensing deals.<\/p>\n

DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.<\/p>\n

DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global\/Enterprise License.<\/p>\n

For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com<\/a><\/p>\n

About Us:<\/strong><\/p>\n

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight, the leading market research and consulting company has added a new report \u201cAntibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016\u201d to its portfolio. The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,173,204,356,386,427,512,558],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-798","post","type-post","status-publish","format-standard","hentry","category-articles","tag-business-consultant","tag-collaborations","tag-delveinsight","tag-licensing-opportunities","tag-market-trends","tag-oncology","tag-reports","tag-technology-assessments","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nAntibody Drug Conjugate Market Insight and Pipeline Insight<\/title>\n<meta name=\"description\" content=\"The Antibody Drug Conjugate Market Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody Drug Conjugate Market Insight and Pipeline Insight\" \/>\n<meta property=\"og:description\" content=\"The Antibody Drug Conjugate Market Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-02-23T05:00:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:25:04+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody Drug Conjugate Market Insight and Pipeline Insight","description":"The Antibody Drug Conjugate Market Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","og_locale":"en_US","og_type":"article","og_title":"Antibody Drug Conjugate Market Insight and Pipeline Insight","og_description":"The Antibody Drug Conjugate Market Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client...","og_url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-02-23T05:00:09+00:00","article_modified_time":"2025-05-05T11:25:04+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report","name":"Antibody Drug Conjugate Market Insight and Pipeline Insight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2016-02-23T05:00:09+00:00","dateModified":"2025-05-05T11:25:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The Antibody Drug Conjugate Market Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-insight-pipeline-assessment-technology-trend-and-competitive-landscape-2016-a-delveinsight-report"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">technology assessments<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Reports<\/span>","<span class=\"advgb-post-tax-term\">technology assessments<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Feb 23, 2016","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Feb 23, 2016 10:30 am","modified":"Updated on May 5, 2025 4:55 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=798"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/798\/revisions"}],"predecessor-version":[{"id":31657,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/798\/revisions\/31657"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=798"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=798"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}